Eli Lilly
80
47M
69
0.54
15
0.12
17
- Areas of investment
Summary
Eli Lilly appeared to be the Corporate Investor, which was created in 1876. The main office of represented Corporate Investor is situated in the Indianapolis. The fund was located in North America if to be more exact in United States.
The common things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Eli Lilly performs on 0 percentage points less the average number of lead investments. The high activity for fund was in 2016. The top amount of exits for fund were in 2019. The fund is constantly included in less than 2 investment rounds annually. The real fund results show that this Corporate Investor is 18 percentage points more often commits exit comparing to other companies.
Besides them, we counted 4 critical employees of this fund in our database.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Eli Lilly, startups are often financed by Skyline Ventures, SV Health Investors, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Innovation, ARCH Venture Partners, Watson Fund. In the next rounds fund is usually obtained by RTW Investments LLC, Zesiger Capital, Unilever Ventures.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Immunocore, Perlegen Sciences, ImmunoGen. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 3 or 4 of the founder, the probability for it to get the investment is little. Among the most popular fund investment industries, there are Biotechnology, Medical. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
Investments analytics
Analytics
- Total investments
- 80
- Lead investments
- 15
- Exits
- 17
- Rounds per year
- 0.54
- Follow on index
- 0.12
- Investments by industry
- Biotechnology (66)
- Health Care (35)
- Pharmaceutical (23)
- Medical (22)
- Therapeutics (20) Show 32 more
- Investments by region
-
- United States (58)
- United Kingdom (10)
- Canada (3)
- France (2)
- China (1) Show 2 more
- Peak activity year
- 2021
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 7M
- Group Appearance index
- 0.82
- Avg. company exit year
- 7
- Avg. multiplicator
- 1.59
- Strategy success index
- 0.80
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Laverock Therapeutics | 28 Sep 2023 | Biotechnology, Therapeutics | Seed | 18M | |
| Lycia Therapeutics | 13 May 2024 | Biotechnology, Health Care, Life Science | Late Stage Venture | 106M | United States, California, San Diego |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.